Ustekinumab - Janssen Biotech

Drug Profile

Ustekinumab - Janssen Biotech

Alternative Names: Anti-interleukin-12 p40 monoclonal antibody; CNTO-1275; STELARA; Stelara; Stellara; Sterrara; Suterara

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Plaque psoriasis; Psoriatic arthritis
  • Phase III Spondylarthritis; Ulcerative colitis
  • Phase II Atopic dermatitis; Systemic lupus erythematosus
  • No development reported Inflammation
  • Discontinued Multiple sclerosis; Palmoplantar pustulosis; Primary biliary cirrhosis; Rheumatoid arthritis; Sarcoidosis

Most Recent Events

  • 06 Nov 2017 Safety and efficacy data from a phase II trial in Systemic lupus erythematosus released by Janssen
  • 06 Nov 2017 Janssen plans a phase III trial for Systemic lupus erythematosus in 2018
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in China (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top